The Novavax Covid-19 vaccine has gained approval for distribution at select general practitioner clinics in Singapore from January 2 to May 31, 2026. This initiative, part of the National Vaccination Programme, aims to enhance community protection against severe Covid-19 illness.
Approval and Availability
On December 30, the Health Sciences Authority granted authorization for the JN.1 Novavax Covid-19 vaccine, designed for individuals aged 12 and older. This vaccine serves as a viable alternative to the LP.8.1 mRNA vaccines, such as Pfizer-BioNTech/Comirnaty and Moderna/Spikevax, which were introduced in October.
Enhanced Protection
The Communicable Diseases Agency (CDA) emphasizes that both the Novavax and mRNA vaccines are expected to boost protection against severe disease. This recommendation is particularly relevant for those who cannot receive mRNA vaccines, excluding individuals with a history of myocarditis or pericarditis following previous mRNA vaccinations.
Importance of Additional Doses
Experts indicate that receiving an additional Covid-19 vaccine dose can significantly enhance immunity against severe disease. Individuals who have not been vaccinated in the past 12 months and wish to receive the Novavax vaccine are encouraged to do so, as immunity can wane over time.
Eligibility Criteria
Those who received vaccines targeting the JN.1 variant in 2024 or 2025 are also eligible for the Novavax vaccine. It is advisable for individuals to get the additional dose approximately one year after their last vaccination to maintain optimal protection.
Time-Sensitive Opportunity
It is crucial to note that this batch of the JN.1 Novavax vaccine will not be available after May 31, 2026. Therefore, eligible individuals should act promptly to secure their vaccinations before the deadline, while the LP.8.1 mRNA vaccines will continue to be accessible.
Targeted Recommendations
Recognizing that Covid-19 waves are likely to persist, the CDA urges those aged 60 and older, as well as medically vulnerable individuals and residents of aged care facilities, to keep their vaccinations up-to-date. This practice mirrors the ongoing recommendations for influenza vaccinations.
Booking an Appointment
Individuals interested in receiving the Novavax vaccine can schedule an appointment at participating GP clinics starting January 2. Those enrolled in the Healthier SG programme are encouraged to visit their designated clinics for vaccination if they provide Covid-19 shots.
Free Vaccination Access
Covid-19 vaccinations remain free for all eligible participants under the National Vaccination Programme, ensuring equitable access to this vital health resource.
The introduction of the Novavax vaccine reflects ongoing efforts to bolster public health amid evolving Covid-19 challenges.
Key Takeaways
- The Novavax Covid-19 vaccine is available in Singapore from January 2 to May 31, 2026.
- It serves as an alternative for those who cannot receive mRNA vaccines.
- Additional doses are crucial for maintaining immunity against severe disease.
- Eligible individuals should act quickly, as the vaccine will expire after May 31, 2026.
- Covid-19 vaccinations continue to be free under the National Vaccination Programme.
In conclusion, the rollout of the Novavax vaccine provides an important opportunity for individuals to enhance their protection against Covid-19. Staying informed and proactive about vaccinations will help safeguard public health as we navigate future challenges.
Read more → www.straitstimes.com